Company profile
aTyr Pharma, Inc.
NASDAQ: ATYR · Healthcare · Biotechnology
#1011 of 1,422 Healthcare companies by revenue28th-percentile growth
EA Score
36DFH 21DQ 57GM 33SS 54
v0.1 · 65/100 weight · provisional
↑ filing timeliness, growth stability · ↓ operating margin, net margin
Methodology →Revenue TTM
$190.0k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$74.1M
Employees
58
as of 2026-08-19
Market cap
$49.4M
as of 2026-08-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$190.0k$190.0k2025
Net income-$74.1M-$74.1M2025
Operating income-$77.6M-$77.6M2025
Total assets$93.0M$93.0M2025
Equity$67.5M$67.5M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY20
FY23
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Collaboration Revenue100%
By geography
Not disclosed.
The read
What is aTyr Pharma, Inc.’s revenue?
aTyr Pharma, Inc. booked $190.0k in FY2025 revenue, contracting 19% year over year — slower than 72% of Healthcare companies we track, at a -39009.5% net margin.
Peers · Healthcare
Windtree Therapeutics, Inc.——CardioComm Solutions, Inc.25DBioxytran, Inc.27DHemp, Inc——NuGen Medical Devices Inc.24DAbpro Holdings, Inc.14DNeighbors
San Diego →Key facts
CEOSanjay S. Shukla
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: ATYR
Employees58
IPO date2015-05-07
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.